TELIX PHARMACEUTICALS LTD(TLX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

TLX.AU TELIX PHARMACEUTICALS LTD

Market Closed 05-03 16:12:00 AEST

15.24

+0.44

+2.97%

High15.24	Low14.61	Vol1.18M
Open14.71	D1 Closing14.80	Amplitude4.26%
Mkt Cap5.04B	Tradable Cap3.95B	Total Shares330.45M
T/O17.69M	T/O Rate0.45%	Tradable Shares259.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.24,"timestamp":1714716720000,"preClose":14.8,"halted":0,"volume":1179463,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":259508440,"shares":330450431,"eps":0.0161,"marketStatus":"Market Closed","change":0.44,"latestTime":"05-03 16:12:00 AEST","open":14.71,"high":15.24,"low":14.61,"amount":17693164,"amplitude":0.042568,"askPrice":15.25,"askSize":10000,"bidPrice":15.15,"bidSize":2333,"shortable":3,"etf":0,"ttmEps":0.0161,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1714953600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":14.8,"openAndCloseTimeList":[[1714694400000,1714716000000]],"volumeRatio":0.8610205696110893,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/TLX.AU","defaultTab":"news","newsList":[{"id":"2432803221","title":"Two high-flying ASX shares: One upgraded, one downgraded","url":"https://stock-news.laohu8.com/highlight/detail?id=2432803221","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2432803221?lang=en_us&edition=fundamental","pubTime":"2024-05-04 02:40","pubTimestamp":1714761600,"startTime":"0","endTime":"0","summary":"Two ASX shares that have made their shareholders smile this year are DroneShield Ltd  and Telix Pharmaceuticals Ltd . Since the start of the year, their shares have risen by approximately 120% and 50%, respectively. As a comparison, the Australian share market is up around 0.5% over the same period. However, one leading broker believes that one of these high-flying ASX shares could have peaked for the time being. This has led to its analysts downgrading its shares to a hold rating. The good news for the other share is that its analysts have gone the other way with it. Despite its very strong gains, the broker has upgraded it to a buy rating from hold this week. Which ASX shares has been downgraded?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/04/two-high-flying-asx-shares-one-upgraded-one-downgraded/","is_publish_highlight":false,"gpt_icon":0},{"id":"2432695404","title":"This fundie invested in Neuren at a $70m valuation. It's now $2.4 billion.","url":"https://stock-news.laohu8.com/highlight/detail?id=2432695404","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2432695404?lang=en_us&edition=fundamental","pubTime":"2024-05-02 09:00","pubTimestamp":1714611605,"startTime":"0","endTime":"0","summary":"The newly minted KP Rx Healthcare Opportunities Fund, managed by Hashan De Silva, comes from a strong pedigree.De Silva previously worked for Karst Peak, a spinoff from Tiger Management, run by legendary hedge fund manager Julian Robertson.Karst Peak founder Adam Leitzes is providing seed capital for KP Rx, following the playbook of Robertson, who seeded and mentored numerous ex-employees to run their own investment houses - affectionately known as \"Tiger cubs\".In addition to the seed capital from Karst Peak, KP Rx’s investors include some of Australia’s most successful healthcare entrepreneurs including Dr Chris Behrenbruch , Patrick Davies , Lou Panaccio  to name a few.The fund is not focused on GP clinics, hospitals, or healthcare services. Rather, it focuses on later-stage businesses, with De Silva describing KP Rx as a \"series A, B, or C investor, where we are coming in once a lot of the initial preclinical stuff has been done.\". Previous successful investments include now ASX-lis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/this-fundie-invested-in-neuren-at-a-70m-valuation-it-s-now-2-4-billion","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/this-fundie-invested-in-neuren-at-a-70m-valuation-it-s-now-2-4-billion","is_publish_highlight":false,"gpt_icon":0},{"id":"2429155171","title":"Why we believe Telix Pharmaceuticals is an attractive investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2429155171","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2429155171?lang=en_us&edition=fundamental","pubTime":"2024-04-23 14:18","pubTimestamp":1713853110,"startTime":"0","endTime":"0","summary":"In the dynamic landscape of investing, uncovering hidden gems amidst the sea of opportunities often requires a keen eye for potential change and growth catalysts. Telix Pharmaceuticals , despite its relatively short tenure on the ASX, emerges as a beacon of promise in the realm of biotech ventures.In evaluating investment opportunities, the lack of an extensive historical record can obscure a company’s growth inflection points, which are critical to our decision-making process. In their absence, we rely on historical analogs from our investment experience to identify key performance indicators. Telix Pharmaceuticals, despite its brief history on the ASX, has demonstrated extraordinary progress by generating over $100 million in revenue in the March 2023 quarter, a remarkable leap from zero, less than twelve months ago. The rapid growth underscores the significant potential of their product offerings.Anticipated growth hinges on Telix’s entry into the radio-diagnostic markets for kidney","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/why-we-believe-telix-pharmaceuticals-is-an-attractive-investment","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/why-we-believe-telix-pharmaceuticals-is-an-attractive-investment","is_publish_highlight":false,"gpt_icon":0},{"id":"2428580434","title":"Why BHP, Challenger, Rio Tinto, and Telix shares are pushing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2428580434","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2428580434?lang=en_us&edition=fundamental","pubTime":"2024-04-18 11:47","pubTimestamp":1713412031,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is back on form and pushing higher on Thursday. In afternoon trade, the benchmark index is up 0.6% to 7,650.2 points. Four ASX shares that are rising more than most tod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/18/why-bhp-challenger-rio-tinto-and-telix-shares-are-pushing-higher-today/","is_publish_highlight":false,"gpt_icon":0},{"id":"2428614333","title":"Press Release: Q1 2024 Revenue and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2428614333","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2428614333?lang=en_us&edition=fundamental","pubTime":"2024-04-17 15:05","pubTimestamp":1713337500,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, April 17, 2024  -- Telix Pharmaceuticals Limited  today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 .The Company reports unaudited total revenue of US$114.9M , an increase of 18% on the prior quarter . Revenue was primarily generated from sales of Telix's prostate cancer imaging product Illuccix.U.S. revenue grew by 18% to US$111.8M , compared to 11% growth between Q3 2023 and Q4 2023.Dr Christian Behrenbruch, Managing Director and Group CEO of Telix, commented, \"The continued, consistent growth of our precision diagnostics business is further evidence of an effective market growth strategy for our prostate cancer franchise. The dual benefit of an early revenue stream, and the ability to fund our late-stage therapeutic programs ensures we are on track to achieve major milestones in 2024 including the progression of three drug approval submissions in the U.S. and the international expansion of our Phase III Pros","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2427827388","title":"QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER","url":"https://stock-news.laohu8.com/highlight/detail?id=2427827388","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2427827388?lang=en_us&edition=fundamental","pubTime":"2024-04-16 20:30","pubTimestamp":1713270600,"startTime":"0","endTime":"0","summary":"Austin, TX, April 16, 2024  -- QSAM Biosciences, Inc.   previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share , at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited   pursuant to which Telix will acquire QSAM .On April 15, 2024, the Board of Directors of QSAM unanimously approved that the reverse stock split ratio be 1-for-2,000 such that once the reverse stock split goes into effect, every holder of Common Stock of the Company shall receive one share of Common Stock for every 2,000 shares of Common Stock held . On February 7, 2024, a majority of the voting shareholders of QSAM approved the reverse stock split and granted the Board the discretion to adopt the ratio prior to the closing of the Merger, which ratio the Board has adopted and is announcing today.Forward-Looking Statements: This release contains","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MjbGsB.uW8zfA8wZQggK4Q--~B/aD0xMDA7dz0yNjQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/00d51fabd4bcd044ccd1544d875406e9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MjbGsB.uW8zfA8wZQggK4Q--~B/aD0xMDA7dz0yNjQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/00d51fabd4bcd044ccd1544d875406e9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qsam-announces-reverse-stock-split-123000802.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427893519","title":"Why Decmil, SCEE, Spartan Resources, and Telix shares are pushing higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2427893519","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2427893519?lang=en_us&edition=fundamental","pubTime":"2024-04-16 11:50","pubTimestamp":1713239458,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) is having a day to forget on Tuesday. In afternoon trade, the benchmark index is down a very disappointing 2.1% to 7,586.6 points. Four ASX shares that are avoiding th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/16/why-decmil-scee-spartan-resources-and-telix-shares-are-pushing-higher/","is_publish_highlight":false,"gpt_icon":0},{"id":"2427857668","title":"BRIEF-Telix Pharmaceuticals Says TLX101-CDX (Pixclara) Granted FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2427857668","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2427857668?lang=en_us&edition=fundamental","pubTime":"2024-04-16 09:29","pubTimestamp":1713230958,"startTime":"0","endTime":"0","summary":"April 16 (Reuters) - Telix Pharmaceuticals Ltd   :   * TLX101-CDX (PIXCLARA) GRANTED FDA FAST TRACK DESIGNATION Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427593758","title":"'Critical unmet need': Why everyone is talking about this ASX 200 healthcare stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2427593758","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2427593758?lang=en_us&edition=fundamental","pubTime":"2024-04-16 08:10","pubTimestamp":1713226206,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd  shares are rising on Tuesday. In morning trade, the ASX 200 healthcare stock is up 1.5% to $13.08. Why is the ASX 200 healthcare stock pushing higher?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/16/critical-unmet-need-why-everyone-is-talking-about-this-asx-200-healthcare-stock/","is_publish_highlight":false,"gpt_icon":0},{"id":"2427085827","title":"Market Open: ASX200 set to shed another 0.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427085827","media":"The Market Herald","top":-1,"share":"https://ttm.financial/m/news/2427085827?lang=en_us&edition=fundamental","pubTime":"2024-04-16 07:16","pubTimestamp":1713222960,"startTime":"0","endTime":"0","summary":"The pain’s set to intensify today, with a 0.8 per cent fall predicted on the ASX200.Retail sales figures in the US came in better than expected, and with fears the Israel, Iran conflict could escalate, gold rose and so did bond yields.The Nasdaq fell 1.8 per cent, the S&P500 dropped a per cent and the Dow Jones well over half a per cent . Customer Relationship Manager platform company, Salesforce, lost more than 7%, with Apple and Visa also losing ground.Perhaps providing insights for this, Rio Tinto  will this morning provide an update to its production for the same period.The Australian dollar has fallen to five-month low of US64.4c, gold is around US$2385  an ounce, iron ore’s been trading just above US$106 a tonne, brent crude is above US$90.50 a barrel, and natural gas has taken a fall of nearly 5 per cent to US$1.68 per million British thermal units.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/market-open-asx200-set-to-shed-another-0-8-2024-04-16/","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://telixpharma.com","stockEarnings":[{"period":"1week","weight":0.0221},{"period":"1month","weight":0.27},{"period":"3month","weight":0.2679},{"period":"6month","weight":0.6494},{"period":"1year","weight":0.3918},{"period":"ytd","weight":0.5119}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.0276},{"period":"3month","weight":0.0615},{"period":"6month","weight":0.1142},{"period":"1year","weight":0.1069},{"period":"ytd","weight":0.0892}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia. Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a development collaboration agreement with ARTMS Products Inc. for the manufacture of its prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET). Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.055106},{"month":2,"riseRate":0.571429,"avgChangeRate":-0.00178},{"month":3,"riseRate":0.857143,"avgChangeRate":0.161224},{"month":4,"riseRate":0.857143,"avgChangeRate":0.098182},{"month":5,"riseRate":0.333333,"avgChangeRate":0.060282},{"month":6,"riseRate":0.666667,"avgChangeRate":0.111666},{"month":7,"riseRate":0.5,"avgChangeRate":0.104857},{"month":8,"riseRate":0.5,"avgChangeRate":-0.036531},{"month":9,"riseRate":0.666667,"avgChangeRate":0.05206},{"month":10,"riseRate":0.833333,"avgChangeRate":0.211878},{"month":11,"riseRate":0.285714,"avgChangeRate":0.007547},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.00088}],"exchange":"ASX","name":"TELIX PHARMACEUTICALS LTD","nameEN":"TELIX PHARMACEUTICALS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TELIX PHARMACEUTICALS LTD(TLX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TELIX PHARMACEUTICALS LTD(TLX.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TELIX PHARMACEUTICALS LTD,TLX.AU,TELIX PHARMACEUTICALS LTD股票,TELIX PHARMACEUTICALS LTD股票老虎,TELIX PHARMACEUTICALS LTD股票老虎国际,TELIX PHARMACEUTICALS LTD行情,TELIX PHARMACEUTICALS LTD股票行情,TELIX PHARMACEUTICALS LTD股价,TELIX PHARMACEUTICALS LTD股市,TELIX PHARMACEUTICALS LTD股票价格,TELIX PHARMACEUTICALS LTD股票交易,TELIX PHARMACEUTICALS LTD股票购买,TELIX PHARMACEUTICALS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TELIX PHARMACEUTICALS LTD(TLX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TELIX PHARMACEUTICALS LTD(TLX.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction